Short Bowel Syndrome clinical trials at University of California Health
2 in progress, 1 open to eligible people
Showing trials for
Feasibility Study to Evaluate Safety and Probable Benefit of the Eclipse XL1 System for Distraction Enterogenesis in Adult and Pediatric Patients With Short Bowel Syndrome
open to eligible people ages 12 months to 65 years
A Feasibility Study to Evaluate Safety and Probable Benefit of the Eclipse XL1 System for Distraction Enterogenesis in Adult and Pediatric Patients with Short Bowel Syndrome
at UCSF
Long-term Safety of Apraglutide in Short Bowel Syndrome.
Sorry, in progress, not accepting new patients
The primary objective of the trial is to assess long-term safety and tolerability of apraglutide in subjects with SBS-IF.
at UCLA
Our lead scientists for Short Bowel Syndrome research studies include Matthew Lin, MD.
Last updated: